AbbVie expands biologics manufacturing capacity in Singapore with $223M investment

AbbVie broke ground on a $223 million expansion of its Singapore manufacturing facility in Tuas Biomedical Park, adding 24,000 liters of biologics drug-substance capacity and over 100 jobs. The expansion is expected to become operational in 2026.

“This expansion announcement represents one of AbbVie's many investments in its Singapore-based operations and the proud continuation of our decade-long partnership with the Government of Singapore.”news.abbvie.com

• 1 source
• news.abbvie.comAbbVie Expands Biologics Manufacturing Capacity with a ...Jan 25, 2024

Summarized from public sources; check the original articles before acting on it.